AlphaGazette
Menu

Science

FDA approves Roche's Wilserdly for breast cancer with an ESR1 mutation

The oral medicine, also called giredestrant, is cleared with everolimus for ER-positive, HER2-negative disease that is locally advanced or metastatic. Roche expects a sales contribution from next year, in line with a consensus of $500-600 million.

1 min read 3 sources AI-generated

The Food and Drug Administration has approved Wilserdly, Roche's oral medicine also called giredestrant, for use together with everolimus. It is cleared for oestrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation when the disease is locally advanced or metastatic.

STAT, which dated the decision to Monday, described eligible patients as those with HR-positive, HER2-negative advanced disease that has gained an ESR1 mutation, evidence the cancer is no longer responding to usual drugs. In the evERA study, this selective estrogen receptor degrader lengthened how long passed before tumors grew again.

The clearance was a regulatory result Roche had been waiting on, and it extends the company's breast-cancer portfolio, built in part through Genentech and the drug Herceptin. Roche has said Wilserdly could become its largest product by sales. The company told AWP that revenue should start next year, that 2027 will be the medicine's first complete year for sale, and that a consensus of $500-600 million matches its expectations. Separately, possible receipts have been set as high as CHF500 million ($592 million) as early as next year. Analysts described the American approval as a "key first step" in the launch.